Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
284
-
Total 13F shares, excl. options
-
24.6M
-
Shares change
-
-391K
-
Total reported value, excl. options
-
$3.35B
-
Value change
-
-$39.9M
-
Put/Call ratio
-
1.72
-
Number of buys
-
159
-
Number of sells
-
-98
-
Price
-
$136.15
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q3 2017
319 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q3 2017.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 284 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.6M shares
.
Largest 10 shareholders include BlackRock Inc. (2.95M shares), VANGUARD GROUP INC (1.77M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.15M shares), BANK OF AMERICA CORP /DE/ (944K shares), STATE STREET CORP (852K shares), Knott David M (798K shares), JANUS HENDERSON GROUP PLC (755K shares), VICTORY CAPITAL MANAGEMENT INC (661K shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (623K shares), and FMR LLC (532K shares).
This table shows the top 284 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.